Diphenylalanine peptide nanotubes achieved 100% kill of mature S. aureus biofilms at 10 mg/mL while remaining safe for mammalian cells — the first time peptide nanotubes have been used to eradicate biofilms.
100% biofilm kill at 10 mg/mLDiphenylalanine peptide nanotubes completely eradicated mature S. aureus biofilms in 24 hours — the first peptide nanotube antibiofilm demonstration
What the researchers found
Self-assembling peptide nanotubes made from diphenylalanine (FF) completely eradicated mature Staphylococcus aureus biofilms — the first time peptide nanotubes have been shown to destroy bacterial biofilms. The NH2-FF-COOH variant was most effective, achieving greater than 99.9% biofilm reduction at 5 mg/mL and complete biofilm kill at 10 mg/mL after 24 hours, with minimal toxicity to mammalian cells.
Scanning electron microscopy revealed the nanotubes work by degrading the biofilm's protective polysaccharide matrix and disrupting bacterial cell membranes through ion channel formation and surfactant-like action. Switching to D-amino acid isomers (NH2-ff-COOH) maintained antibiofilm activity, while amidated forms (NH2-FF-NH2) were more toxic and less effective.
Why it matters
Bacterial biofilms are one of the biggest unsolved problems in medicine. These slimy communities of bacteria are 10 to 10,000 times more resistant to antibiotics than free-floating bacteria, causing chronic infections on medical devices, wounds, and implants. This study is the first to show that simple two-amino-acid peptide nanotubes can destroy these biofilms entirely. Because diphenylalanine peptides self-assemble into nanostructures spontaneously, they could be relatively cheap and easy to manufacture compared to complex antibiotics.
The numbers in context
>99.9% biofilm reduction at 5 mg/mL · complete kill at 10 mg/mL · 24h exposure · >3 Log10 CFU/mL reduction · biofilms 10-10,000× more antibiotic-resistant than planktonic bacteria
How the study worked
The researchers synthesized three variants of diphenylalanine peptide nanotubes with different terminal functional groups. They tested antibacterial activity against both planktonic (free-floating) and biofilm forms of hospital-associated bacteria, including S. aureus. Mammalian cell toxicity was assessed using fibroblasts and hemolysis assays. Scanning electron microscopy was used to visualize how the nanotubes interact with biofilm structures and bacterial membranes.
Who was studied
In vitro study using bacterial cultures (Staphylococcus aureus and other hospital infection-associated bacteria) and mammalian cell lines
What this study cannot tell us
This is an in vitro (lab-based) study. The concentrations needed to kill biofilms (5-10 mg/mL) are relatively high, and it's unclear whether these can be safely achieved in a clinical setting. Activity was primarily demonstrated against Gram-positive bacteria, with limited data on Gram-negative organisms. No animal or human testing was conducted.
How to read the evidence
This is a well-designed in vitro study that provides the first proof-of-concept for peptide nanotube antibiofilm activity. The methodology is thorough, with multiple peptide variants tested, toxicity profiling, and electron microscopy visualization. However, as a lab-based study with no animal or human data, it remains at the early preclinical stage.
When this study was published
Published in 2018, this study introduced the concept of peptide nanotube antibiofilm activity. Research in this area has likely progressed since, with potential follow-up studies testing these structures in animal models or developing practical delivery systems.
The bigger picture
Biofilm infections account for up to 80% of all chronic bacterial infections and are a leading cause of antibiotic resistance. Current antibiotics often fail against biofilms because the protective matrix prevents drugs from reaching the bacteria inside. Peptide nanotubes represent an entirely new approach — instead of trying to get drugs through the biofilm, these structures physically destroy the biofilm matrix itself. If this technology can be scaled and delivered effectively, it could provide a fundamentally different weapon against one of medicine's most intractable infection problems.
Questions still open
- Can the concentrations needed for biofilm eradication (5-10 mg/mL) be safely achieved in clinical applications like wound dressings or medical device coatings?
- Would these peptide nanotubes also work against Gram-negative bacterial biofilms, which have different membrane structures?
- Could peptide nanotubes be combined with conventional antibiotics for a synergistic biofilm-destroying effect?
Common questions
What is a bacterial biofilm and why is it so hard to treat?
How do peptide nanotubes destroy biofilms differently from antibiotics?
Read the original research
Self-assembling diphenylalanine peptide nanotubes selectively eradicate bacterial biofilm infection.
Acta biomaterialia, 77, 96-105
Citation
Porter, Simon L; Coulter, Sophie M; Pentlavalli, Sreekanth; Thompson, Thomas P; Laverty, Garry. (2018). Self-assembling diphenylalanine peptide nanotubes selectively eradicate bacterial biofilm infection.. Acta biomaterialia, 77, 96-105. https://doi.org/10.1016/j.actbio.2018.07.033